Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors
暂无分享,去创建一个
F. D. De Braud | A. Scarpa | M. Falconi | N. Fazio | G. Capurso | G. delle Fave | M. Brizzi | L. Dogliotti | P. Tomassetti | G. Di Meglio | D. Campana | L. Boninsegna | F. Panzuto | F. Nori | Francesca Nori
[1] J. Stockman,et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .
[2] B. Wiedenmann,et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor‐node‐metastasis classification determines clinical outcome , 2011, Cancer.
[3] A. Scarpa,et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Ellis,et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[6] M. Coleman,et al. Carcinoid Tumors of the Gastrointestinal Tract: Trends in Incidence in England Since 1971 , 2010, The American Journal of Gastroenterology.
[7] B. Niederle,et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. , 2010, Endocrine-related cancer.
[8] R. Salazar,et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] William Mantovani,et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients , 2010, Modern Pathology.
[10] C. Schade-Brittinger,et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. King,et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. , 2009, Endocrine-related cancer.
[12] T. de Baère,et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. , 2009, Endocrine-related cancer.
[13] M. Vatn,et al. Small intestinal neuroendocrine tumors: Prognostic factors and survival , 2009, Scandinavian journal of gastroenterology.
[14] C. Doglioni,et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. , 2009, Human pathology.
[15] S. Willich,et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. , 2008, Endocrine-related cancer.
[16] B. Skogseid,et al. Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.
[17] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Scarpa,et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] R. Jensen,et al. Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.
[20] B. Wiedenmann,et al. Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma , 2007, Neuroendocrinology.
[21] A. Scarpa,et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.
[22] B. Diggs,et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. , 2006, Surgery.
[23] D. Santini,et al. Endocrine Tumors of the Ileum: Factors Correlated with Survival , 2006, Neuroendocrinology.
[24] B. Weinhold. Epigenetics: The Science of Change , 2006, Virchows Archiv.
[25] M. Falconi,et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. , 2005, Endocrine-related cancer.
[26] W. Hiddemann,et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[27] A. Grossman,et al. The diagnosis and medical management of advanced neuroendocrine tumors. , 2004, Endocrine reviews.
[28] Lawrence H Schwartz,et al. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. , 2004, Journal of clinical epidemiology.
[29] R. DeLellis. Pathology and genetics of tumours of endocrine organs , 2004 .
[30] U. Mansmann,et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] G. Åkerström,et al. Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver Metastases , 2002, World Journal of Surgery.
[32] G. Pelosi,et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. , 1996, Human pathology.